CA_Chetanbhasin

AstraZeneca

Long
CA_Chetanbhasin Updated   
NSE:ASTRAZEN   ASTRAZENECA PHARMA
AstraZenecaa Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products

The company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England

The company offers pharmaceutical medicines under notable brands such as Brilinta, Forxiga, Crestor, Tagrisso, Calquence, Zoladex, Symbicort, and a few more. These brands cater to various medical areas, including Cardiovascular, Renal, and Metabolic (CVRM) Diseases, Oncology, Respiratory, and Immunology, etc

FY 23 the revenue mix of the company was

Oncology - 56% in FY23 vs 47% in FY22 
Cardiovascular - 27% in FY23 28% in FY22 
Diabetes - 14% in FY23 vs 22% in FY22
Respiratory - 4% in FY23 vs 3% in FY22

Fundamentally- the company generates a ROCE of 30.9% > Cost of capital with Debt to equity of 0.1. PEG of 1.2 suggest stock is fairly valued

Technically- RSI above 70 suggest stock is bullish and in process of forming Cup and holder, breakout above 4920 could likely to take the stock to 6470 levels
Comment:
AstraZeneca recommended at 4700, reached 5600 levels

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.